Ex Vivo Human Placental Transfer of Anti-Human Immunodeficiency Virus Compounds
1997
Transfer of HIV Drugs Through the Placenta
Sample size: 20
publication
Evidence: moderate
Author Information
Author(s): Roger E. Bawdon
Primary Institution: University of Texas Southwestern Medical Center
Hypothesis
The study investigates the transfer of anti-HIV drugs through the human placenta using an ex vivo model.
Conclusion
The study found that various anti-HIV drugs can cross the human placenta, although at different rates.
Supporting Evidence
- All tested anti-HIV drugs crossed the placenta by simple diffusion.
- Ritonavir diffused more slowly than nucleosides but still crossed the placenta.
- Combination therapies may be necessary to prevent HIV resistance.
Takeaway
This study shows that some HIV medicines can pass from a mother to her baby through the placenta, which is important for treating pregnant women with HIV.
Methodology
The study used a standardized ex vivo human placental model to measure the transfer of anti-HIV drugs.
Limitations
The ex vivo model cannot fully replicate the pharmacokinetics in pregnant women.
Participant Demographics
The study involved HIV-positive pregnant women.
Want to read the original?
Access the complete publication on the publisher's website